The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
18F-dopa and S-11C-nomifensine (NMF) are positron emitting tracers whose caudate and putamen uptake reflects striatal dopamine storage capacity and the integrity of dopamine reuptake sites, respectively. Using these two tracers, the integrity of the presynaptic striatal dopaminergic system has been studied with positron emission tomography (PET) in 10 subjects with multiple system atrophy (MSA, Shy-Drager syndrome) who had an akinetic-rigid syndrome that was poorly responsive to L-dopa, autonomic failure, and cerebellar ataxia. PET findings for the 10 MSA patients were compared with those for 13 age-matched controls, 8 subjects with L-dopa responsive Parkinson's disease (PD), and 7 subjects with pure autonomic failure (PAF). Influx constants, Ki, reflecting specific 18F-dopa uptake into striatal tissue, were severely reduced in the putamen and caudate of the 10 MSA subjects (mean putamen Ki 0.005 min-1 MSA vs 0.013 min-1 controls; mean caudate Ki 0.007 min-1 MSA vs 0.013 min-1 controls). Reduction of putamen, but not caudate, 18F-dopa uptake correlated with severity and duration of locomotor disability. Eight patients with PD, and a similar degree and duration of locomotor disability to the patients with MSA, demonstrated equal impairment of mean putamen 18F-dopa uptake, but significant preservation of mean caudate function. The 7 PAF patients had normal mean levels of putamen and caudate 18F-dopa uptake, although 1 individual PAF patient had significantly impaired striatal function. The MSA and PD groups of subjects both showed significantly reduced levels of specific striatal S-11C-NMF binding, again caudate function being relatively preserved in PD. It is concluded that in both MSA and PD there is a parallel decline of striatal dopamine storage capacity and reuptake site integrity, probably reflecting a loss of nigrostriatal nerve terminals. Caudate function is relatively preserved in PD compared with MSA. The majority of PAF patients have an intact nigrostriatal dopaminergic system, suggesting that PAF is a condition distinct from PD and MSA in spite of some pathological similarities. PET is capable of detecting subclinical nigrostriatal involvement in PAF patients when this is present.
Brooks
D J
DJ
MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
Salmon
E P
EP
Mathias
C J
CJ
Quinn
N
N
Leenders
K L
KL
Bannister
R
R
Marsden
C D
CD
Frackowiak
R S
RS
D000328:Adult; D000368:Aged; D001284:Atrophy; D001341:Autonomic Nervous System / Q000000981:diagnostic imaging / Q000503:physiopathology; D001342:Autonomic Nervous System Diseases / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000503:physiopathology*; D004295:Dihydroxyphenylalanine / Q000493:pharmacokinetics; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D008124:Locomotion; D008875:Middle Aged; D009627:Nomifensine / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D014055:Tomography, Emission-Computed
D009627:Nomifensine; D004295:Dihydroxyphenylalanine; D004298:Dopamine